Search

A Special Coach for the Cantera 2024

A unique tutorial for young hematologists, co-sponsored by the EHA Lymphoma Group and the Fondazione Italiana Linfomi. DatesMay 14 to May 17, 2024. LocationLecce, Italy. TopicHow the utilization of cellular therapy strategies looks for lymphomas in 2024.

Read more

Apply to be a Master Class mentee

Applications closed on July 15, 2024

EligibilityTo apply to be a menteee, you must be one of the following:

A hematologist
Receiving hematology training
Seeing hematology patients
You must also be an EHA member.

Read more

Highlights from the SWG

The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.

Read more

Strengthening Resilience and Fostering Collaboration: Ensuring a Transparent and Reliable Supply Chain for Plasma-Derived Products

The issue of immunoglobulin shortages and the importance of enhancing and maintaining plasma supplies have gained significant attention within the policy and regulatory landscape of the European Union.

Read more

Proposal for an EU Regulation on Clinical Trials: A joint statement from non-commercial and commercial organisations

This statement outlines the areas of agreement within the health and research communities on where the Regulation will improve the research environment. Aspects of the Regulation that could be improved to further support clinical research are also highlighted.

Read more

The European Hematology Association (EHA) Announces a New Era of Partnership with Interplan as its New Core PCO

The European Hematology Association (EHA) is delighted to announce to the conference and meeting community the outcome of its Core PCO Invitation To Tender (ITT).

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…

Read more

Evaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER

Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.

Read more